WASHINGTON, D.C. (Azat TV) – The COVID-19 variant BA.3.2, nicknamed “Cicada,” is increasingly detected across the United States and at least 23 countries worldwide, drawing close monitoring from public health officials due to its extensive mutations that may allow it to evade immunity from vaccines or prior infections. While it has not yet triggered a major surge in cases or severe illness, its spread highlights ongoing vulnerabilities in global COVID-19 control efforts.
What is the BA.3.2 ‘Cicada’ COVID Variant?
First identified in South Africa in November 2024, BA.3.2 is a descendent of the earlier BA.3 Omicron subvariant. It remained under the radar for nearly two years but began spreading more noticeably in September 2025. BA.3.2 has acquired approximately 75 mutations in its spike protein, distinguishing it genetically from previously dominant variants like Nimbus and XFG. These mutations potentially reduce recognition by antibodies generated from prior infection or vaccination, according to experts such as Dr. Andrew Pekosz of Johns Hopkins Bloomberg School of Public Health.
Despite these changes, laboratory studies suggest the virus’s altered spike protein may bind less efficiently to human cells, possibly limiting its infectiousness. The World Health Organization (WHO) classified BA.3.2 as a “variant under monitoring” in February 2026, reflecting caution but no immediate alarm.
Where Is BA.3.2 Spreading and How Prevalent Is It?
As of February 2026, BA.3.2 has been detected in wastewater and clinical samples from at least 25 US states, including California, New York, Florida, and Texas. Though it accounts for a small fraction of cases domestically (less than 1% nationwide), it represents about 30% of COVID-19 sequences in several Northern European countries such as Germany, Denmark, and the Netherlands.
Surveillance programs like WastewaterSCAN report BA.3.2 in roughly 3.7% of wastewater samples in the US, while other variants such as XFG remain dominant. Experts note that reduced testing and monitoring complicate precise assessments of BA.3.2’s spread.
Symptoms and Severity of BA.3.2 Infections
Current evidence shows that BA.3.2 causes symptoms typical of COVID-19 infections, including cough, fever or chills, sore throat, congestion, fatigue, headache, and gastrointestinal issues. There is no indication that this variant leads to more severe disease or higher hospitalization rates. Dr. Adolfo García-Sastre from Mt. Sinai emphasized that despite its genetic changes, BA.3.2 has yet to cause a significant clinical impact.
Public health experts recommend standard precautions for symptomatic individuals: testing, isolation if positive, and mask-wearing in crowded indoor settings. COVID antiviral treatments remain effective against BA.3.2, providing additional options for managing illness.
Vaccine Effectiveness and Public Health Implications
The extensive mutations in BA.3.2’s spike protein raise concerns about vaccine escape. Laboratory data suggest reduced neutralization by antibodies elicited by current vaccines targeting other lineages, though vaccines still provide protection against severe illness and death. Annual vaccine updates are expected to incorporate emerging variants to maintain effectiveness.
Experts urge vaccination, especially for vulnerable populations such as older adults and immunocompromised individuals. Maintaining boosters and public health measures, including testing and mask use when appropriate, remain critical to limiting spread and severe outcomes.
While BA.3.2 has not yet triggered a major wave, its persistence and gradual rise underscore the unpredictable nature of COVID-19’s evolution. Continued surveillance and vaccine adaptation are essential to managing this and future variants.
The emergence of BA.3.2 highlights how COVID-19 continues to mutate in ways that challenge existing immunity, yet so far it has not overwhelmed healthcare systems or caused widespread severe illness. This variant’s gradual spread serves as a reminder that vigilant monitoring and adaptable vaccines remain essential tools in the ongoing pandemic response.